COLLABORATION GROUP FOR RENAL CANCER - NoRenCa

From left: Christian Beisland (N), Pernilla Sundqvist (S), Frode S. Nilsen (N),

Nessn Azawi (DK), Lars Lund (Chairman) (DK), Börje Ljungberg (S),

Eirikur Gudmundsson (IS) Petrus Järvinen (F), Harry Nisen (F)

Members of NoRenCa

Denmark:

Lars Lund, Odense University Hospital, Chairman (see picture)

Nessn Azawi, Roskilde University Hospital

Sweden:

Pernilla Sundquist, Örebro (see picture)

Börje Ljungberg, Umeå (see picture)

Finland:

Harry Nisen, Helsinki (see picture)

Järvinen Petrus, Helsinki

Norway:

Christian Beisland, Bergen (see picture)

Frode S Nilsen, Oslo (see picture)

Iceland:

Eiríkur Orri Guðmundsson, Reykjavik (see picture)

NoRenCa study 1 – Contemporary treatment of renal tumours in the Nordic countries.  

Results presented at EAU 2017 in London

Literature

 

Nisen H, Järvinen P, Fovaeus M, Guðmundsson E, Kromann-Andersen B, Ljungberg B, Lund L, Nilsen F, Sundqvist P, Beisland C.

Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the NORENCA-I study).

Scand J Urol. 2017 Oct;51(5):360-366. doi: 10.1080/21681805.2017.1326524.

Lund L, Nisen H, Järvinen P, Fovaeus M, Gudmundsson E, Kromann-Andersen B, Ljungberg B, Nilsen F, Sundqvist P, Clark PE, Beisland C.

Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study)

Res Rep Urol. 2018 Oct 25;10:181-187. doi: 10.2147/RRU.S177774. eCollection 2018

B. Ljungberg (Chair), L. Albiges, K. Bensalah, A. Bex (Vice-chair), R.H. Giles (Patient Advocate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi, A.S. Merseburger, T. Powles, M. Staehler, A. Volpe Guidelines Associates: Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello Montes, F. Hofmann, T. Kuusk, R. Tahbaz

EAU Guidelines on Renal Cell Carcinoma

EAU Pocket Guidelines on Renal Cell Carcinoma

RENAL CELL CARCINOMA – LIMITED UPDATE MARCH 2019

Loren Lipworth, Robert E Tarone, Lars Lund, Joseph K McLaughlin

Epidemiologic characteristics and risk factors for renal cell cancer

Clinical Epidemiology 2009:1 33–43

Sebastiano Buti, Pierre I. Karakiewicz, Melissa Bersanelli, Umberto Capitanio, ZheTian, Alessio Cortellini, SatoruTaguchi, Alberto Briganti, Francesco Montorsi, Francesco Leonardi, Marco Bandini

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Scientific Reports (2019) 9:13218 | https://doi.org/10.1038/s41598-019-49250-6

Nessn H. Azawi, Maria Skydt Lindgren, Ida Uhrskov Ibsen, Sara Tolouee, Naomi Nadler, Claus Dahl & Mikkel Fode

Novel technique: direct access partial nephrectomy approach through a transperitoneal working space (Roskilde technique)

SCANDINAVIAN JOURNAL OF UROLOGY 2019, VOL. 53, NO. 4, 261–264 https://doi.org/10.1080/21681805.2019.1624609

Information for Patients: Kidney Cancer

Information for Patients: Antiangiogenic therapy

Information for Patients: Immunotherapy in Kidney Cancer

Present Ph-D studies in renal cancers

Denmark:

– KIDSTAGE by Louise Geertsen, Odense Universitetshospital.

Sweden:

– Anna Landberg, Dep of Urology, Örebro University, Örebro